The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia

New England Journal of Medicine

Volumn 335, Issue 8, 1996, Pages 533-539

  Lepor, Herbert ^a   Williford, William O ^b   Barry, Michael J ^c   Brawer, Michael K ^d   Dixon, Christopher M ^a   Gormley, Glenn ^e   Haakenson, Clair ^f   Machi, Madeline ^g   Narayan, Perinchery ^b   Padley, Robert J ^h  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f VA Medical Center   (United States)

^g CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEADACHE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCORING SYSTEM; SINUSITIS; SYMPTOMATOLOGY; SYNCOPE; URINE FLOW RATE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES; PRAZOSIN; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URODYNAMICS;

EID: 9444268678     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608223350801     Document Type: Article

References (24)

1. Bartsch G, Muller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979;122:487-91.
2. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992;21:297-307.
3. Madsen FA, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia. Urol Clin North Am 1995;22:291-8.
4. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243-7.
5. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-91.
6. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-9.
7. Beisland HO, Binkowitz B, Brekkan E, et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992;22:271-7.
8. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467-74.
9. Brawer MK, Adams G, Epstein H, Terazosin Benign Prostatic Hyperplasia Study Group. Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 1993;2:929-35.
10. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995;154:105-9.
11. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995;154:110-5.
12. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990; 144:908-11.
13. 1c antagonist. J Urol 1995;153:Suppl: 274A. abstract.
14. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148:1549-57.
15. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995;33:Suppl:AS145-AS155.
16. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4.
17. Greene DR, Egawa S, Hellerstein DK, Scardino PT. Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology 1990;36:293-7
18. Schluchter MD. BMDP-5V unbalanced repeated measures models with structured covariance matrices. Technical report no. 86. Los Angeles: BMDP Statistical Software, 1988.
19. Miller RG Jr. Simultaneous statistical inference. New York: McGraw-Hill, 1960.
20. Lepor H. The role of alpha blockade in the therapy of benign prostatic hyperplasia. In: Lepor H, Lawson RK, eds. Prostate diseases. Philadelphia: W.B. Saunders, 1993:170-81.
21. Gup DI, Shapiro E, Baumann M, Lepor H. Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 1989;15:105-14.
22. McConnell JD. Benign prostatic hyperplasia: hormonal treatment. Urol Clin North Am 1995;22:387-400.
23. Berger BM, Naadimuthu A, Boddy A, et al. The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. J Urol 1995;154:1060-4.
24. Stone NN, Lepor H, Crawford ED, et al. Dose ranging study of the antiandrogen flutamide in men with benign prostatic hyperplasia (BPH): effect on prostate volume and serum prostate specific antigen (PSA) level. J Urol 1996;155:Suppl:575A. abstract.